A hidden weakness in deadly cancers could lead to powerful new treatments

UCLA researchers have discovered a critical vulnerability in aggressive small cell cancers that have resisted new treatments for decades. The study found that tumors lacking the RB gene become dependent on the protein E2F3 for survival. By blocking E2F3, scientists successfully shut down tumor growth in laboratory models, and existing FDA-approved drugs may exploit this weakness. This breakthrough could accelerate the development of more effective therapies for patients with small cell cancer, offering hope for a disease that has had limited treatment options.